MDM2 and ameloblastoma: Those findings are in line with previous studies [10,12,13,60,61] that by employing various molecular techniques, e.g., microarrays, RNA-sequencing, Sanger sequencing, and polymerase chain reaction (PCR), highlighted the differential expression and/or mutations of other molecular markers that do not predict MDM2 mutations in ameloblastoma.